 |
PDBsum entry 1xbb
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Transferase
|
 |
|
Title:
|
 |
Crystal structure of the syk tyrosine kinase domain with gleevec
|
|
Structure:
|
 |
Tyrosine-protein kinase syk. Chain: a. Synonym: spleen tyrosine kinase. Engineered: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Gene: syk. Expressed in: spodoptera frugiperda. Expression_system_taxid: 7108. Expression_system_cell_line: sf9.
|
|
Resolution:
|
 |
|
1.57Å
|
R-factor:
|
0.191
|
R-free:
|
0.221
|
|
|
Authors:
|
 |
V.L.Nienaber,S.Atwell,J.M.Adams,J.Badger,M.D.Buchanan,I.K.Feil, K.J.Froning,X.Gao,J.Hendle,K.Keegan,B.C.Leon,H.J.Muller-Deickmann, B.W.Noland,K.Post,K.R.Rajashankar,A.Ramos,M.Russell,S.K.Burley, S.G.Buchanan
|
Key ref:
|
 |
S.Atwell
et al.
(2004).
A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase.
J Biol Chem,
279,
55827-55832.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
30-Aug-04
|
Release date:
|
02-Nov-04
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P43405
(KSYK_HUMAN) -
Tyrosine-protein kinase SYK from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
635 a.a.
268 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.2.7.10.2
- non-specific protein-tyrosine kinase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + ADP + H+
|
 |
 |
 |
 |
 |
L-tyrosyl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-tyrosyl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
J Biol Chem
279:55827-55832
(2004)
|
|
PubMed id:
|
|
|
|
|
| |
|
A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase.
|
|
S.Atwell,
J.M.Adams,
J.Badger,
M.D.Buchanan,
I.K.Feil,
K.J.Froning,
X.Gao,
J.Hendle,
K.Keegan,
B.C.Leon,
H.J.Müller-Dieckmann,
V.L.Nienaber,
B.W.Noland,
K.Post,
K.R.Rajashankar,
A.Ramos,
M.Russell,
S.K.Burley,
S.G.Buchanan.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase required for
signaling from immunoreceptors in various hematopoietic cells. Phosphorylation
of two tyrosine residues in the activation loop of the Syk kinase catalytic
domain is necessary for signaling, a phenomenon typical of tyrosine kinase
family members. Syk in vitro enzyme activity, however, does not depend on
phosphorylation (activation loop tyrosine --> phenylalanine mutants retain
catalytic activity). We have determined the x-ray structure of the
unphosphorylated form of the kinase catalytic domain of Syk. The enzyme adopts a
conformation of the activation loop typically seen only in activated,
phosphorylated tyrosine kinases, explaining why Syk does not require
phosphorylation for activation. We also demonstrate that Gleevec (STI-571,
Imatinib) inhibits the isolated kinase domains of both unphosphorylated Syk and
phosphorylated Abl with comparable potency. Gleevec binds Syk in a novel,
compact cis-conformation that differs dramatically from the binding mode
observed with unphosphorylated Abl, the more Gleevec-sensitive form of Abl. This
finding suggests the existence of two distinct Gleevec binding modes: an
extended, trans-conformation characteristic of tight binding to the inactive
conformation of a protein kinase and a second compact, cis-conformation
characteristic of weaker binding to the active conformation. Finally, the
Syk-bound cis-conformation of Gleevec bears a striking resemblance to the rigid
structure of the nonspecific, natural product kinase inhibitor staurosporine.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 2.
FIG. 2. Stereo view of alternate Gleevec binding modes.
Gleevec bound to unphosphorylated Abl (green) adopts an
extended, trans-confirmation, which is incompatible with the
phosphorylated/more active confirmation of Abl (blue). Gleevec
binds to the unphosphorylated/active confirmation of Syk
(yellow) in a very different cis-conformation, which is more
compatible with binding to the phosphorylated/more active
conformation of Abl (blue). The key residues are labeled.
|
 |
Figure 4.
FIG. 4. A, binding of Gleevec to Syk. Ligand difference
electron density (2 F[observed]-F[calculated]) contoured at 1
.
B, binding of Gleevec and staurosporine to Syk. Gleevec (yellow)
binding to Syk in the compact cis-conformation mimics the
structure and binding mode of staurosporine (salmon). The key
residues are labeled, and hydrogen bonds are denoted with dashed
lines. The images were prepared with Xfit (25).
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from the ASBMB:
J Biol Chem
(2004,
279,
55827-55832)
copyright 2004.
|
|
| |
Figures were
selected
by the author.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
D.G.Efremov,
and
L.Laurenti
(2011).
The Syk kinase as a therapeutic target in leukemia and lymphoma.
|
| |
Expert Opin Investig Drugs,
20,
623-636.
|
 |
|
|
|
|
 |
S.S.Taylor,
and
A.P.Kornev
(2011).
Protein kinases: evolution of dynamic regulatory proteins.
|
| |
Trends Biochem Sci,
36,
65-77.
|
 |
|
|
|
|
 |
A.G.Villaseñor,
A.Wong,
A.Shao,
A.Garg,
A.Kuglstatter,
and
S.F.Harris
(2010).
Acoustic matrix microseeding: improving protein crystal growth with minimal chemical bias.
|
| |
Acta Crystallogr D Biol Crystallogr,
66,
568-576.
|
 |
|
|
|
|
 |
B.A.Shoemaker,
D.Zhang,
R.R.Thangudu,
M.Tyagi,
J.H.Fong,
A.Marchler-Bauer,
S.H.Bryant,
T.Madej,
and
A.R.Panchenko
(2010).
Inferred Biomolecular Interaction Server--a web server to analyze and predict protein interacting partners and binding sites.
|
| |
Nucleic Acids Res,
38,
D518-D524.
|
 |
|
|
|
|
 |
D.Singh,
R.Rani,
R.Rajendran,
N.J.Kaur,
A.Pandey,
P.Chopra,
T.Jain,
M.K.Jain,
S.Grover,
R.Arya,
and
K.S.Saini
(2010).
Human spleen tyrosine kinase (Syk) recombinant expression systems for high-throughput assays.
|
| |
Biotechnol J,
5,
201-212.
|
 |
|
|
|
|
 |
F.M.Uckun,
and
S.Qazi
(2010).
Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.
|
| |
Expert Rev Anticancer Ther,
10,
1407-1418.
|
 |
|
|
|
|
 |
J.B.Bruning,
A.A.Parent,
G.Gil,
M.Zhao,
J.Nowak,
M.C.Pace,
C.L.Smith,
P.V.Afonine,
P.D.Adams,
J.A.Katzenellenbogen,
and
K.W.Nettles
(2010).
Coupling of receptor conformation and ligand orientation determine graded activity.
|
| |
Nat Chem Biol,
6,
837-843.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
L.M.Wodicka,
P.Ciceri,
M.I.Davis,
J.P.Hunt,
M.Floyd,
S.Salerno,
X.H.Hua,
J.M.Ford,
R.C.Armstrong,
P.P.Zarrinkar,
and
D.K.Treiber
(2010).
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
|
| |
Chem Biol,
17,
1241-1249.
|
 |
|
|
|
|
 |
M.Rabiller,
M.Getlik,
S.Klüter,
A.Richters,
S.Tückmantel,
J.R.Simard,
and
D.Rauh
(2010).
Proteus in the world of proteins: conformational changes in protein kinases.
|
| |
Arch Pharm (Weinheim),
343,
193-206.
|
 |
|
|
|
|
 |
A.Dixit,
and
G.M.Verkhivker
(2009).
Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations.
|
| |
PLoS Comput Biol,
5,
e1000487.
|
 |
|
|
|
|
 |
A.G.Villaseñor,
R.Kondru,
H.Ho,
S.Wang,
E.Papp,
D.Shaw,
J.W.Barnett,
M.F.Browner,
and
A.Kuglstatter
(2009).
Structural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexes.
|
| |
Chem Biol Drug Des,
73,
466-470.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
A.Torkamani,
G.Verkhivker,
and
N.J.Schork
(2009).
Cancer driver mutations in protein kinase genes.
|
| |
Cancer Lett,
281,
117-127.
|
 |
|
|
|
|
 |
E.Arias-Palomo,
M.A.Recuero-Checa,
X.R.Bustelo,
and
O.Llorca
(2009).
Conformational rearrangements upon Syk auto-phosphorylation.
|
| |
Biochim Biophys Acta,
1794,
1211-1217.
|
 |
|
|
|
|
 |
H.Nakano,
and
S.Omura
(2009).
Chemical biology of natural indolocarbazole products: 30 years since the discovery of staurosporine.
|
| |
J Antibiot (Tokyo),
62,
17-26.
|
 |
|
|
|
|
 |
J.A.Winger,
O.Hantschel,
G.Superti-Furga,
and
J.Kuriyan
(2009).
The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2).
|
| |
BMC Struct Biol,
9,
7.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.C.Spalton,
J.Mori,
A.Y.Pollitt,
C.E.Hughes,
J.A.Eble,
and
S.P.Watson
(2009).
The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets.
|
| |
J Thromb Haemost,
7,
1192-1199.
|
 |
|
|
|
|
 |
P.Dubreuil,
S.Letard,
M.Ciufolini,
L.Gros,
M.Humbert,
N.Castéran,
L.Borge,
B.Hajem,
A.Lermet,
W.Sippl,
E.Voisset,
M.Arock,
C.Auclair,
P.S.Leventhal,
C.D.Mansfield,
A.Moussy,
and
O.Hermine
(2009).
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.
|
| |
PLoS One,
4,
e7258.
|
 |
|
|
|
|
 |
R.L.Geahlen
(2009).
Syk and pTyr'd: Signaling through the B cell antigen receptor.
|
| |
Biochim Biophys Acta,
1793,
1115-1127.
|
 |
|
|
|
|
 |
S.Gobessi,
L.Laurenti,
P.G.Longo,
L.Carsetti,
V.Berno,
S.Sica,
G.Leone,
and
D.G.Efremov
(2009).
Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells.
|
| |
Leukemia,
23,
686-697.
|
 |
|
|
|
|
 |
B.D.Marsden,
and
S.Knapp
(2008).
Doing more than just the structure-structural genomics in kinase drug discovery.
|
| |
Curr Opin Chem Biol,
12,
40-45.
|
 |
|
|
|
|
 |
C.Harbert,
J.Marshall,
S.Soh,
and
K.Steger
(2008).
Development of a HTRF kinase assay for determination of Syk activity.
|
| |
Curr Chem Genomics,
1,
20-26.
|
 |
|
|
|
|
 |
M.D.Jacobs,
P.R.Caron,
and
B.J.Hare
(2008).
Classifying protein kinase structures guides use of ligand-selectivity profiles to predict inactive conformations: structure of lck/imatinib complex.
|
| |
Proteins,
70,
1451-1460.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
N.Katayama,
M.Orita,
T.Yamaguchi,
H.Hisamichi,
S.Kuromitsu,
H.Kurihara,
H.Sakashita,
Y.Matsumoto,
S.Fujita,
and
T.Niimi
(2008).
Identification of a key element for hydrogen-bonding patterns between protein kinases and their inhibitors.
|
| |
Proteins,
73,
795-801.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
E.Arias-Palomo,
M.A.Recuero-Checa,
X.R.Bustelo,
and
O.Llorca
(2007).
3D structure of Syk kinase determined by single-particle electron microscopy.
|
| |
Biochim Biophys Acta,
1774,
1493-1499.
|
 |
|
|
|
|
 |
G.M.Verkhivker
(2007).
In silico profiling of tyrosine kinases binding specificity and drug resistance using Monte Carlo simulations with the ensembles of protein kinase crystal structures.
|
| |
Biopolymers,
85,
333-348.
|
 |
|
|
|
|
 |
G.M.Verkhivker
(2007).
Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.
|
| |
Proteins,
66,
912-929.
|
 |
|
|
|
|
 |
J.A.Frearson,
P.G.Wyatt,
I.H.Gilbert,
and
A.H.Fairlamb
(2007).
Target assessment for antiparasitic drug discovery.
|
| |
Trends Parasitol,
23,
589-595.
|
 |
|
|
|
|
 |
M.A.Seeliger,
B.Nagar,
F.Frank,
X.Cao,
M.N.Henderson,
and
J.Kuriyan
(2007).
c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty.
|
| |
Structure,
15,
299-311.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.Ikuta,
M.Kornienko,
N.Byrne,
J.C.Reid,
S.Mizuarai,
H.Kotani,
and
S.K.Munshi
(2007).
Crystal structures of the N-terminal kinase domain of human RSK1 bound to three different ligands: Implications for the design of RSK1 specific inhibitors.
|
| |
Protein Sci,
16,
2626-2635.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
S.W.Cowan-Jacob,
G.Fendrich,
A.Floersheimer,
P.Furet,
J.Liebetanz,
G.Rummel,
P.Rheinberger,
M.Centeleghe,
D.Fabbro,
and
P.W.Manley
(2007).
Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia.
|
| |
Acta Crystallogr D Biol Crystallogr,
63,
80-93.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
D.K.Walters,
T.Mercher,
T.L.Gu,
T.O'Hare,
J.W.Tyner,
M.Loriaux,
V.L.Goss,
K.A.Lee,
C.A.Eide,
M.J.Wong,
E.P.Stoffregen,
L.McGreevey,
J.Nardone,
S.A.Moore,
J.Crispino,
T.J.Boggon,
M.C.Heinrich,
M.W.Deininger,
R.D.Polakiewicz,
D.G.Gilliland,
and
B.J.Druker
(2006).
Activating alleles of JAK3 in acute megakaryoblastic leukemia.
|
| |
Cancer Cell,
10,
65-75.
|
 |
|
|
|
|
 |
G.M.Verkhivker
(2006).
Imprint of evolutionary conservation and protein structure variation on the binding function of protein tyrosine kinases.
|
| |
Bioinformatics,
22,
1846-1854.
|
 |
|
|
|
|
 |
J.P.Overington,
B.Al-Lazikani,
and
A.L.Hopkins
(2006).
How many drug targets are there?
|
| |
Nat Rev Drug Discov,
5,
993-996.
|
 |
|
|
|
|
 |
T.L.Nguyen,
R.Gussio,
J.A.Smith,
D.A.Lannigan,
S.M.Hecht,
D.A.Scudiero,
R.H.Shoemaker,
and
D.W.Zaharevitz
(2006).
Homology model of RSK2 N-terminal kinase domain, structure-based identification of novel RSK2 inhibitors, and preliminary common pharmacophore.
|
| |
Bioorg Med Chem,
14,
6097-6105.
|
 |
|
|
|
|
 |
T.L.Sorensen,
K.E.McAuley,
R.Flaig,
and
E.M.Duke
(2006).
New light for science: synchrotron radiation in structural medicine.
|
| |
Trends Biotechnol,
24,
500-508.
|
 |
|
|
|
|
 |
Y.Liu,
and
N.S.Gray
(2006).
Rational design of inhibitors that bind to inactive kinase conformations.
|
| |
Nat Chem Biol,
2,
358-364.
|
 |
|
|
|
|
 |
C.Gambacorti-Passerini,
M.Gasser,
S.Ahmed,
S.Assouline,
and
L.Scapozza
(2005).
Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies.
|
| |
Leukemia,
19,
1267-1269.
|
 |
|
|
|
|
 |
M.Marzec,
M.Kasprzycka,
A.Ptasznik,
P.Wlodarski,
Q.Zhang,
N.Odum,
and
M.A.Wasik
(2005).
Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3.
|
| |
Lab Invest,
85,
1544-1554.
|
 |
|
|
|
|
 |
N.J.de Mol,
M.I.Catalina,
F.J.Dekker,
M.J.Fischer,
A.J.Heck,
and
R.M.Liskamp
(2005).
Protein flexibility and ligand rigidity: a thermodynamic and kinetic study of ITAM-based ligand binding to Syk tandem SH2.
|
| |
Chembiochem,
6,
2261-2270.
|
 |
|
|
|
|
 |
S.W.Cowan-Jacob,
G.Fendrich,
P.W.Manley,
W.Jahnke,
D.Fabbro,
J.Liebetanz,
and
T.Meyer
(2005).
The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation.
|
| |
Structure,
13,
861-871.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
T.Brdicka,
T.A.Kadlecek,
J.P.Roose,
A.W.Pastuszak,
and
A.Weiss
(2005).
Intramolecular regulatory switch in ZAP-70: analogy with receptor tyrosine kinases.
|
| |
Mol Cell Biol,
25,
4924-4933.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |